Trial Profile
Sifrol Onset of Action and Impact: a 12-Weeks Observational Study in Patients With Primary RLS.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2014
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 03 Jun 2014 Primary endpoint of safety has been added as reported by ClinicalTrials.gov record.
- 12 Jan 2010 Actual patient number (549) added as reported by ClinicalTrials.gov.
- 05 Mar 2009 Planned number of patients changed from 500 to 540 as reported by ClinicalTrials.gov.